Linagliptin: The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

Cardiology in Review

Volumn 20, Issue 1, 2012, Pages 45-51

  Aletti, Rachael ^a   Cheng Lai, Angela ^a  

^a Jack D Weiler Hospital   (United States)

Author keywords

diabetes mellitus; dipeptidyl peptidase 4 inhibitors; incretin therapy; linagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; LINAGLIPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHOSPASM; COUGHING; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG STRUCTURE; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN EXFOLIATION; TREATMENT CONTRAINDICATION; URTICARIA; WEIGHT GAIN;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PURINES; QUINAZOLINES; TABLETS; TREATMENT OUTCOME;

EID: 83155190231     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31823a3afc     Document Type: Article

References (34)

1. World Health Organization. Diabetes: fact sheet (no.312). August 2011. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 14 August, 2011.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. (Pubitemid 38579764)
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
4. Wackers FJ. Diabetes and coronary artery disease: the role of stress myocardial perfusion imaging. Cleve Clin J Med. 2005;72:21-25, 29.
5. Dall T, Nikolov P, Hogan PF. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.
6. American Diabetes Association. Standards of medical care in Diabetes. Diabetes Care. 2011;34(Suppl 1):S11-S61.
7. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 (Suppl 2):1-53.
8. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3-18.
9. Nanuk MA. Unraveling the science of incretin biology. Am J Med. 2009;122 (6 Suppl):S3-S10.
10. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123(3 Suppl):S28-S37.
11. Thomas L, Eckhardt M, Langkopf E, et al. ®-8-(3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175-182. (Pubitemid 351439162)
12. Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:542-550.
13. Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther. 2011;33:973-989.
14. Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786-794.
15. Hüttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48:1171-1178.
16. TradjentaTM [package insert]. Ridgefield, CT: Boehringer Ingelheim International; July, 2011.
17. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of ß-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-267.
18. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
19. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:653-661.
20. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24 week randomized study. Poster 548-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June, 2010, Orlando, Florida, USA.
21. Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2011;36:17-24.
22. Graefe-Mody U, Huettner S, Stähle H, et al. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010;48:367-374.
23. Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25:1963-1972.
24. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multipledose study. Clin Drug Investig. 2011;31:643-653.
25. Graefe-Mody EU, Brand T, Ring A, et al. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int J Clin Pharmacol Ther. 2011;49:300-310.
26. Graefe-Mody EU, Jungnik A, Ring A, et al. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2010;48:652-661.
27. Graefe-Mody U, Rose P, Ring A, et al. Assessment of the Pharmacokinetic Interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011;26:123-129.
28. Januiva® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; April, 2011.
29. OnglyzaTM [package insert]. Princeton, NJ: Bristol-Myers Squibb; February, 2011.
30. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648-658.
31. Choy M, Lam S. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Cardiol Rev. 2007;15:264-271. (Pubitemid 47282035)
32. Lam S, Saad M. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010;18:213-217.
33. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
34. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.